$MYO

Mitchell Micah sold $78K of MYO

Mitchell Micah (Chief Commercial Officer) sold 90,231 shares of MYOMO, INC. (MYO) at $0.86 on 2026-05-14.

Original reporting
SEC EDGAR · Mitchell Micah
Published Jun 8, 2026, 8:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MYO
Neutral
high confidence
Mentioned
$MYO
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MYONeutralLow
01

Why it matters

This adds a new, primary-source datapoint on insider ownership changes, but it does not disclose any new company operational or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The article provides only the sale details; it does not include context like option exercises, compensation timing, or whether other insiders are buying/selling around the same period.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-08 (covers sale dated 2026-05-14).

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for MYOMO, Inc. (MYO).

Company-level read

Ticker impact

$MYONeutralHigh confidence
Context

SEC Form 4 shows MYO chief commercial officer Mitchell Micah sold 90,231 shares in an open-market transaction on 2026-05-14.

Expected impact

Low near-term impact; any effect is likely sentiment-only unless follow-on filings show accelerated selling or other corporate developments.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan and no accompanying company-specific news (earnings, guidance, contracts, litigation, or regulatory action) in the article.

Market effects

No sector-level read-across; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; absence of a stated 10b5-1 plan does not automatically imply negative fundamentals.

Key entities

  • MYOMO, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Mitchell Micah

    Chief Commercial Officer who sold shares via an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MYOMedAI 8/10

Myomo Q2 Earnings Call Highlights

Myomo (MYO) said MyoConnect referrals rose to 17% of Q2 pipeline additions from 11% in Q1. Of 739 patients added, about 122 came from referrals. Gross margin increased to 72.1% from 62.7%. Q2 net loss was $4.0M ($0.09/share). Q3 revenue guidance is $11.5M to $12.0M, and full-year revenue outlook raised to $45M to $47M.

$MYOHigh

MYOMO, INC. (MYO): Results of Operations and Financial Condition

MYOMO, INC. (MYO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Myomo Reports Second Quarter 2026 Financial and Operating Results Revenue of $11.7 million, increased 21% year over year Four success pillars driving higher revenue growth and operating leverage Raising full year revenue guidance to $45-47 million Conference call beg

$RGNTMedAI 8/10

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Regentis (RGNT) shares rose 526.7% after it withdrew a planned SEC Form F-1 for a firm-commitment offering of 3.33M shares at an assumed $3.00. Cuprina (CUPR) jumped 111.8% after FDA clearance for MEDIFLY maggots for debridement of non-healing wounds. Intellia (NTLA) gained 23.2% on additional Phase 3 results for hereditary angioedema; it targets approval and a 1H 2027 launch.

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.